Article
24 Jun 2026
Eli Lilly’s 340B Claims-Data Policy: What Covered Entities Need To Know
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
24 Jun 2026
Prior Authorization By A Third Party: What Pharmacies Need To Know Before The PBM Audit Comes
Article
24 Jun 2026
CMS Signals The Next Major Phase Of PBM Reform: Why Pharmacies And Plan Sponsors Should Pay Attention Now
Article
24 Jun 2026
HRSA’s 340B Rebate Model Is Moving Faster Than Many Expected: What Covered Entities Should Be Doing Now
Article
23 Jun 2026
Express Scripts Challenges Tennessee Fair Rx Act: Another Attempt To Preserve The Status Quo
Article
09 Jun 2026
Federal And State Program-Integrity Scrutiny Of Pharmacies Is Increasing: What Pharmacies Need To Know
Article
01 Jun 2026
Pharmacy Change Of Ownership Transactions: Why CHOW Must Be Handled Correctly
Article
27 May 2026
The No Surprises Act Is Becoming A Legal And Reimbursement Trap For Providers
Article
17 May 2026
The Evolving Responsibilities Of Pharmacists Amid Rising DEA Investigations: What Pharmacies Need To Know Before Agents Walk Through The Door
Article
11 May 2026
Tennessee’s FAIR Rx Act Marks A Major Escalation In State PBM Reform
Article
06 May 2026
The Illusion Of PBM Transparency: What Plan Sponsors Must Learn From The OPM OIG Audit Of CVS Caremark
Article
06 May 2026
What FDA’s Latest Peptide Action Really Means For Compounding Pharmacies
Article
06 May 2026
Peptides At The Crossroads: FDA Tightens The Line As Category 2 Pushes Toward Category 1
Article
27 Mar 2026
Board Of Pharmacy Enforcement Is Accelerating: What Pharmacies And Industry Stakeholders Need To Do Now
Article
23 Mar 2026
The Consolidated Appropriations Act Of 2026: What Plan Sponsors And Pharmacies Need To Know And How To Use It
Article
18 Mar 2026
Multi-Year Insurance Audits Of Physical Therapy Practices: Documentation, Medical Necessity, And The Growing Use Of Extrapolation
Article
18 Mar 2026
ERISA Class Action on Prescription Drug Benefits Gets Green Light — A Warning for Plan Sponsors
Article
13 Mar 2026
State Enforcement Against Pharmacy Benefit Managers Intensifies: Lessons From Louisiana And West Virginia
Article
13 Feb 2026
Oral Semaglutide And The GLP-1 Compounding Reckoning: From Regulatory Ambiguity To FDA Enforcement, DOJ Referrals, And Novo Nordisk's Case Against Hims & Hers
Article
28 Jan 2026
California's PBM Fiduciary Law Faces An ERISA Challenge – Why This Matters For Independent Pharmacies And Patients
